http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H1081623-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e45efeaa6a34dfd9d44fa29a7fe0c806
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
filingDate 1997-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c59b86a80a9ef9ff6999c9be6d1566d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eba18c53107ac9cb9f0b276eb6b22ff6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3412687ebfc52c46ec39f74e5002adcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_974194fdccb5a8553106b3f44fc2fe59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d72ce51c32f1db6d4e8183685c0c5d67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_928a3d09f55269476abe923fac91797d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21979881628b7d90df64c967050026ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4b4419fd7d6186aeb81d60dfabac025
publicationDate 1998-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H1081623-A
titleOfInvention Autoimmune disease therapeutic agent
abstract (57) [Summary] [PROBLEMS] To provide a therapeutic agent for an autoimmune disease. SOLUTION: 4- (2-chlorophenyl) -2- (2 -(4-Isobutylphenyl) ethyl) -6,9-dimethyl-6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepine, its optics It has been found that isomers, or their pharmaceutically acceptable acid addition salts or hydrates, can achieve the above objectives.
priorityDate 1997-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410862584
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119175
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27435
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419724716
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415819605
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394775
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID519065
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419567187
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457521271
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19088442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2265
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60606
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534242
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID519065

Total number of triples: 42.